Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Defense was posted on February 28, 2013. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

65--Benzodiazepine Urine Immunoassay Reagent - Detection of Nordiazepam, Oxazepam, Temazepam, Lorazepam, and Alpha-Hydroxyalprazolam Abuse in Urine

Awarded
N6264513R0012Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

2 days ago

DEADLINE

in 4 days
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 5 days
NAICS: 325413
Federal
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Solicitation # HT942627QE003
The Defense Health Agency is soliciting quotations to establish a Blanket Purchase Agreement (BPA) for the recurring resupply of consumable products for three Terumo Trima Accel Blood Collection Systems used by the USAISR Combat Casualty Care Research Team 1 in Texas. To maintain FDA approval and satisfy research protocols, the contractor must provide original manufacturer-supplied consumables, including Teruflex 500ml collection bags, Trima Platelet Kits, Isoplate Solution (PAS-F), TSCD Wafers, ACD-A Solution, and 150 mL couplers. This procurement is a 100 percent set-aside for Service-Disabled Veteran-Owned Small Businesses under NAICS 325413. The resulting BPA will have a 60-month ordering period with a total ceiling of 35 million dollars, though some documentation notes a lower limit of 350,000 dollars. Individual call orders are capped at 50,000 dollars, while Government Purchase Card orders are limited to 15,000 dollars. Awards will be made on a Lowest Price Technically Acceptable basis, with technical capability rated as pass or fail. All payment requests and receiving reports must be processed electronically through the Wide Area WorkFlow system. Quotations are due by November 6, 2026, and must be submitted in two separate volumes covering technical capability and pricing.
Army Medical Resources Acq Activity

POSTED

7 days ago

DEADLINE

in 7 days

AI Contract Overview

Show more

The Naval Medical Logistics Command intends to establish a sole source, firm fixed price requirements contract with Microgenics Corporation to provide Benzodiazepine Reagent Kits for Department of Defense Drug Demand Reduction Program Laboratories. This procurement is necessary because the Microgenics Cloned Enzyme Drug Immuno Assay is the only commercially available immunoassay compatible with the Hitachi Modular Clinical Analyzers used across various Navy, Army, and Air Force laboratories. The contract period begins on March 1, 2013, and extends through February 28, 2018, consisting of a base period and five subsequent option periods. Classified under NAICS 325413, the acquisition follows FAR Part 12 and FAR 16.5 guidelines with no set-aside restrictions. While intended as a sole source award, the government allowed for the submission of technical capability statements from other interested parties to determine if competitive procurement was warranted.

General Info

Contract Value

$0

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

MD, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

1 update
PhaseAwarded
Posted

Presolicitation

Justification (J&A)

Justification & Approval published

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Naval Medical Logistics Command
ContactsNo contacts available
OfficeFORT DETRICK, MD, 21702-9203, USA
Office AddressFORT DETRICK, MD, 21702-9203, USA
ContactsNo contact information available

Full Description

Show more
The Naval Medical Logistics Command (NMLC) intends to establish a firm fixed price requirements contract on a sole source basis (IAW FAR 6.302-1) with the Microgenics Corporation, 46360 Fremont Boulevard, Fremont, California 94538, as the only source that can provide Benzodiazepine Reagent Kits to the Department of Defense (DoD) Drug Demand Reduction Program (DDRP) Laboratories. The laboratories include: Navy Drug Screening Laboratory (NDSL) Great Lakes, Illinois; NDSL Jacksonville, Florida; NDSL San Diego, California; Army Forensic Toxicology Drug Testing Laboratory (AFTDTL) Fort Meade, Maryland; AFTDTL Tripler Army Medical Center (AMC), Hawaii; Headquarters Air Force Drug Testing Laboratory (HQ AFDTL) Lackland Air Force Base, Texas; and Armed Forces Medical Examiner System (AFMES) Dover Air Force Base (AFB), Delaware. Specifically, the Microgenics Corporation’s Cloned Enzyme Drug Immuno Assay (CEDIA) high sensitivity assay is the only commercially available immunoassay that includes B-glucuronidase and is compatible with the Hitachi Modular (D&P) Clinical Analyzers in use at the DoD DDRP Laboratories. Microgenics is the only response source and no other supplies or services will satisfy agency requirements. The proposed requirements contract shall have the following period of performance: Base Period 01 March 2013 – 30 September 2013 Option Period 01: 01 October 2013 – 30 September 2014 Option Period 02: 01 October 2014 – 30 September 2015 Option Period 03: 01 October 2015 – 30 September 2016 Option Period 04: 01 October 2016 – 30 September 2017 Option Period 05: 01 October 2017 – 28 February 2018 This acquisition is being conducted in accordance with FAR Part 12 and FAR 16.5. There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 325413 with a Small Business Size Standard of 500. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same service. All capability statements received within 15 days after publication of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Capability statements shall be submitted by email only as an MS Word or Adobe PDF attachment to Shannon Hess at contact@example.gov (in subject line you shall reference: N62645-13-R-0012 Benzodiazepine Reagent Kits). Statements are due no later than 06 January 2013, 04:30 PM local time. No phone calls accepted.

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS